戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ancomycin for definitive therapy but not for empiric treatment.
2 of guideline adherence on appropriateness of empiric treatment.
3 e often lacking, leading to the necessity of empiric treatment.
4  effectiveness of assay-guided treatment and empiric treatment.
5 signed patients to assay-guided treatment or empiric treatment.
6 rent asthma subtypes into a single group for empiric treatment.
7 o monitor antimicrobial resistance and guide empiric treatment.
8  health concern, threatening the efficacy of empiric treatment.
9 fomycin, suggesting a potential for these as empiric treatments.
10 ive microbiology resulted in less changes of empiric treatment (33 [40%] vs 112 [60%]; p=0.005) and s
11 nosed with a stepwise approach incorporating empiric treatment and antisecretory therapy, combined MI
12 s among all isolates with the following: (1) empiric treatment (B and C), and treatment guided by POC
13 instructed versus induced patients initiated empiric treatment based on clinical and radiography find
14 tion antibiograms can be generated to inform empiric treatment changes in nonresponding patients.
15 se) to guide treatment changes compared with empiric treatment changes, and the benefits and risks of
16 tential clinical and public health impact on empiric treatment, contact investigation, and housing in
17 duce the frequency and impact of unnecessary empiric treatment, contact investigation, and housing, p
18 ity and mortality make early recognition and empiric treatment critical.
19 l of the benefits and risks that result from empiric treatment decisions that are based on resistance
20 st step in bridging the gap between RMDs and empiric treatment decisions.
21                                Approaches to empiric treatment, duration of therapy, and other manage
22     The patient's condition worsened despite empiric treatment for an infectious etiology.
23 mpiric treatment of febrile neutropenia, and empiric treatment for hemodynamic instability.
24                        In patients receiving empiric treatment for sepsis, prior colonization with 3G
25  children and should prompt consideration of empiric treatment for SFR when present.
26 children, and should prompt consideration of empiric treatment for SFR when present.
27  Therapeutic plasma exchange is an effective empiric treatment for thrombotic thrombocytopenic purpur
28 e therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection.
29 ere larger for antibiotics commonly used for empiric treatment (HR = 1.18; 95% CI, 1.10-1.26).
30 e treatment, thereby mitigating the need for empiric treatment.IMPORTANCENucleic acid amplification t
31 ame-day diagnoses, and-because of widespread empiric treatment-may not result in more patients starti
32                          Even with prompt or empiric treatment, mortality and neurodevelopmental impa
33 bility of definitive treatment compared with empiric treatment occurred in 26% of cases, increasing f
34 when prescribing oral cephalosporins for the empiric treatment of community-acquired bacterial pneumo
35 Knowledge of regional AMR rates helps inform empiric treatment of community-onset uUTI and highlights
36 idime-avibactam was highly effective for the empiric treatment of cUTI (including acute pyelonephriti
37 ng to narrow spectrum antibiotics during the empiric treatment of E. coli bacteraemia by quantifying
38 tching to narrow spectrum antibiotics in the empiric treatment of E. coli bacteraemia.
39                                          For empiric treatment of febrile dysenteric diarrhea invasiv
40 e to beta-lactam agents commonly used in the empiric treatment of febrile neutropenia was observed on
41  for preengraftment neutropenia prophylaxis, empiric treatment of febrile neutropenia, and empiric tr
42                               For first-line empiric treatment of H pylori infection, vonoprazan trip
43 rming levels and is compromising traditional empiric treatment of H. pylori.
44 f ceftazidime and tobramycin for the initial empiric treatment of hospital-acquired bacterial pneumon
45 nd/or multidosed antibiotic regimens for the empiric treatment of intraabdominal infections.
46 lness with no laboratory-confirmed etiology, empiric treatment of iNTS disease is a major challenge i
47 ong turnaround times (TATs) that necessitate empiric treatment of many patients who ultimately are fo
48 tance to 4 beta-lactams commonly used in the empiric treatment of neutropenic fever.
49 cological principles will help guide optimal empiric treatment of outpatient UTIs.
50                                   Successful empiric treatment of patients with the hypereosinophilic
51 nerally is the recommendation as the initial empiric treatment of suspected bacterial endophthalmitis
52 d change of antibiotic classes, used for the empiric treatment of suspected gram-negative bacterial i
53 neration cephalosporin (ceftazidime) for the empiric treatment of suspected gram-negative bacterial i
54 T/NG/MG assay may help to reduce reliance on empiric treatment of symptoms and minimize resulting ret
55                                 The mainstay empiric treatments of bacterial endophthalmitis are intr
56 score the urgent threat to ceftriaxone as an empiric treatment option.
57 , imipenem and vancomycin remain appropriate empiric treatment options for R. equi.
58 to adapt therapy in patients unresponsive to empiric treatment options, which occurs in 10% of all ca
59 ver, delays in receiving results can lead to empiric treatment, potentially causing misdiagnosis and
60 health strategies to inform surveillance and empiric treatment protocols.
61  of nESBL-PE infections, potentially guiding empiric treatment recommendations.
62 epresenting a progressively broader spectrum empiric treatment regimen, were used to compare outcomes
63 prophylaxis regimens, programs should devise empiric treatment regimens that are directed against the
64 s (LBCLs) with inferior responses to current empiric treatment regimens.
65                                Approaches to empiric treatment selection, duration of therapy, and ot
66                                              Empiric treatment should be considered for ELBW infants
67 tigations led to revised recommendations for empiric treatment strategies and additional management d
68 erratically and, instead, clinicians rely on empiric treatment strategies and ignore public health im
69                                              Empiric treatment strategies for diarrheal disease in we
70 ure and do not account for adaptation during empiric treatment that can alter S. aureus' susceptibili
71                                Approaches to empiric treatment, transitioning to oral therapy, durati
72                                Approaches to empiric treatment, transitioning to oral therapy, durati
73        Women without infections who received empiric treatment were more likely have recurrent visits
74 h to determine the appropriate threshold for empiric treatment when PE is suspected before diagnostic
75  platelet count remained at 2000/mm3 despite empiric treatment with intravenous immune globulin and m
76                  We were unable to show that empiric treatment with OAD was associated with a worse o
77 patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed
78                                    Continued empiric treatment without POC testing was projected to r